Search company, investor...
RevBio company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Grant - II | Alive

Total Raised


About RevBio

RevBio is engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite. It serves clients in the healthcare sector. RevBio was formerly known as LaunchPad Medical. The company was founded in 2016 and is based in Lowell, Massachusetts.

RevBio Headquarters Location

600 Suffolk Street Suite 250

Lowell, Massachusetts, 01854,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RevBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RevBio is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Dental Health

957 items

Companies delivering dental care products and services. Excludes practice networks.


Health IT

7,901 items

RevBio Patents

RevBio has filed 1 patent.

The 3 most popular patent topics include:

  • Biomaterials
  • Calcium compounds
  • Food additives
patents chart

Application Date

Grant Date


Related Topics




Phosphates, Calcium compounds, Food additives, Biomaterials, Proteinogenic amino acids


Application Date


Grant Date



Related Topics

Phosphates, Calcium compounds, Food additives, Biomaterials, Proteinogenic amino acids



Latest RevBio News

RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology

Sep 20, 2022

This Grant will Advance the Company’s Pre-Clinical Research to Demonstrate an Improvement to the Current Standard of Care for Spine Fractures. Download Pre-clinical testing of the percutaneous injection of TETRANITE to treat a vertebral compression fracture. (Photo: Business Wire) September 20, 2022 08:00 AM Eastern Daylight Time LOWELL, Mass.--( BUSINESS WIRE )--RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is injectable, the material may be delivered in a minimally invasive procedure. “The adhesive and structural features of this biomaterial combined with the fact that it is osteoconductive and ultimately replaced by bone make it an excellent candidate for an improved vertebroplasty procedure,” said Dr. Kevin T. Foley M.D., Professor of Neurosurgery, Orthopedic Surgery, and Biomedical Engineering at the University of Tennessee Health Science Center, Chairman of the Semmes Murphey Spinal Care Clinic, and a recognized pioneer in the development of minimally invasive spine surgery. “This regenerative, adhesive, and cohesive material delivered percutaneously could significantly improve the way these fractures are treated.” In the United States, approximately 700,000 vertebral compression fractures (“VCF”) occur each year, costing an estimated $250 million in Medicare-related expenses. These compression fractures are most common among elderly individuals. Historically, VCFs have been primarily treated using vertebroplasty and kyphoplasty, which are techniques involving the injection of polymethylmethacrylate (PMMA) into the vertebral body through a transpedicular approach under fluoroscopy. However, more recent clinical evidence has shown that these procedures are extremely risky with significant complications. Most concerning is the risk of extravasation, or cement leakage, which has occurred in up to 75% of all reported cases in published literature with up to 23% resulting in pulmonary emboli. It is therefore not surprising that the prevalence of these procedures decreased by more than 70% from their peak since this information has come to light. “This opportunity complements the indications we are currently pursuing in dentistry, cranial surgery, orthopaedic trauma procedures, and animal health indications,” said Brian Hess, CEO of RevBio. The successful completion of the research awarded in this Phase I grant will put RevBio on track to apply for a larger, Phase II grant which would provide approximately $2 million in follow-on funding for this project. This research is supported by the National Institute on Aging, grant number 1R43AG079741-01A1. About RevBio, Inc. RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use. Contacts

  • When was RevBio founded?

    RevBio was founded in 2016.

  • Where is RevBio's headquarters?

    RevBio's headquarters is located at 600 Suffolk Street, Lowell.

  • What is RevBio's latest funding round?

    RevBio's latest funding round is Grant - II.

  • How much did RevBio raise?

    RevBio raised a total of $17.81M.

  • Who are the investors of RevBio?

    Investors of RevBio include National Institute of Aging, Paycheck Protection Program, MassChallenge and Boston Harbor Angels.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.